{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.252","value":"1.89"},{"groupId":"OG001","spread":"0.466","value":"1.44"},{"groupId":"OG003","spread":"0.589","value":"1.46"},{"groupId":"OG004","spread":"0.287","value":"1.43"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"title":"Single-dose"},{"categories":[{"measurements":[{"groupId":"OG003","spread":"0.181","value":"1.10"},{"groupId":"OG004","spread":"1.33","value":"1.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"title":"Multiple-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"9"}],"units":"Participants"}],"description":"PK assessment of VRx-3996 pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1","dispersionType":"Standard Deviation","groups":[{"description":"VRx-3996: 5 mg BID valganciclovir: 450 mg BID","id":"OG000","title":"Phase 1b Dose Escalation Cohort 2a"},{"description":"VRx-3996: 10 mg QD or BID valganciclovir: 450 mg QD or BID or 900 mg QD or BID","id":"OG001","title":"Phase 1b Dose Escalation Cohorts 1, 2b and 2c"},{"description":"VRx-3996: 20 mg QD on Days 1 to 4/week valganciclovir: 900 mg QD","id":"OG002","title":"Phase 1b Dose Escalation Cohort 3"},{"description":"VRx-3996: 20 mg QD on Days 1 to 4/week valganciclovir: 900 mg QD","id":"OG003","title":"Phase 2 RP2D - Capsule"},{"description":"VRx-3996: 20 mg QD on Days 1 to 4/week valganciclovir: 900 mg QD","id":"OG004","title":"Phase 2 RP2D - Tablet"}],"paramType":"MEAN","populationDescription":"The PK Analysis Set was used for all PK analyses and included all patients in the intent-to-treat population (defined as all enrolled patients) who had at least one postdose measurable PK concentration. The PK Analysis Set will be used for individual plasma concentration listings and summaries of plasma concentrations.","reportingStatus":"POSTED","timeFrame":"Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1","title":"Half-life of VRx-3996","type":"SECONDARY","unitOfMeasure":"hours"}